CTRI/2024/01/061470尚未招募2 期
Clinical Pharmacokinetic Study of Quercetin Extracts in Healthy Human Volunteers. - Nil
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- Tilman SA
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Healthy male and female human trial participants aged between 18 and 45 years (both inclusive); 2. Female trial participants must have a negative urine pregnancy test prior to the housing3. Male and females agreeing to use the contraceptive pill or abstinence as a method of contraception during and 07 days after completion of the study;4. Trial participants with a BMI between 18.50-28.00 kg per m2 and body mass, not less than 50.00 kg;5. Trial participants in normal health as determined by personal medical history, clinical examination including vital signs, and clinically acceptable results of laboratory examinations (including serological tests);6. Trial participants having a normal or clinically not significant 12-lead electrocardiogram (ECG) recording;7. Trial participants having a normal or clinically not significant chest X-ray (PA view);8. A negative alcohol breath test result;9. Trial participant able to communicate effectively and provide written informed consent; 10. Trial participants willing to adhere to the protocol requirements as evidenced by written informed consent approved by the ethics committee;11. Trial participants that can provide adequate evidence of their identity;12. Availability of volunteers for the entire study duration;13. Ability to fast for at least 14.00 hours and consume standard meals.
排除标准
- •1. Known hypersensitivity to Quercetin or related product or any component of this intervention;
- •2. Incapable of understanding the informed consent information;
- •3. Clinically significant medical condition, such as, but not limited to, cardiovascular, neurological, psychiatric, pulmonary, renal, immunological, endocrine (including uncontrolled diabetes or thyroid disease), or uncontrolled haematological abnormalities;
- •4. Any treatment which could bring about induction or inhibition of the hepatic microsomal enzyme system within one month of starting the study;
- •5. History or presence of alcoholism or drug abuse;
- •6. History or presence of asthma, urticaria, or other allergic reactions;
- •7. History or presence of gastric and or duodenal ulceration;
- •8. History or presence of thyroid disease, adrenal dysfunction, or organic intracranial lesion;
- •9. History or presence of cancer;
- •10. Difficulty with donating blood;
- •11. Use of any prescribed medication (including herbal remedies) during the two weeks before the start of the study or OTC medicinal products (including herbal remedies) during the week before study initiation and throughout the study;
- •12. Use of medications such as benzodiazepines, anticonvulsants, or barbiturates for one month before the start of the study and throughout the study;
- •13. Smokers who smoke 9 or more cigarettes per day or inability to abstain during the study;
- •14. Trial participant consumed tobacco or tobacco-containing products, pan or pan masala, gutkha, and masala (containing beetle nut and tobacco) for at least 48.00 hours before initiation of the study and throughout the study;
- •15. Trial participant consumed caffeine and or xanthine-containing foods or beverages (i.e., coffee, tea, chocolate, and caffeine-containing sodas, colas, etc.) and grapefruit juice and poppy-containing foods for at least 48.00 hours before initiation of the study and throughout the study;
- •16. Major illness during the 90 days before screening;
- •17. Participation in a drug research study within 90 days of screening;
- •18. Donation of blood within 90 days of screening;
- •19. Positive screening test result for any one or more of the following: HIV, Hepatitis B, Hepatitis C, and VDRL;
- •20. History or presence of easy bruising or bleeding;
- •21. Abnormal diet pattern for whatever reason (e.g., low sodium, fasting, and high protein diets) during the four weeks preceding the study;
- •22. Females of childbearing potential with any one of the following reported and documented on the medical history:
- •i. Postmenopausal with spontaneous amenorrhea for at least one year, or
- •ii. Bilateral oophorectomy with or without a hysterectomy and an absence of bleeding for at least 6 months, or
- •iii. Total hysterectomy and an absence of bleeding for at least 3 months;
- •23. Pregnant women and nursing mothers;
- •24. Male and females of childbearing potential unwilling to employ appropriate and reliable method of contraception during the study till 07 days after the completion of the study;
- •25. Male volunteers willing to donate sperm during the study till 07 days after the completion of the study.
- •26. Consumption of dietary supplements likely to provide polyphenols and Quercetine.
研究者
相似试验
尚未招募
不适用
Pharmacokinetics of high dose quercetin – a potential treatment for asthmaRespiratory - AsthmaAsthmaACTRN12622000074796eon Huang30
已完成
2 期
Quercetin in thalassemiabeta thalassemia major.Cooley anaemia Severe beta thalassaemia Thalassaemia: intermedia majorIRCT201701172709N43Vice chancellor for research, Iran University of Medical Sciences84
已完成
不适用
Pharmacokinetic of quercetin in tears following oral ingestiodry eye diseaseJPRN-UMIN000037092Tokyo Dental College10
已完成
不适用
Effect of co-administration of quercetin on the endothelial dysfunction after continuous treatment of nitroglycerin in Japanese volunteers with aldehyde dehydrogenase2 *2 polymorphism: randomized crossover trialangina pectorisJPRN-UMIN000033639SOUSEIKAI Fukuoka Mirai Hospital, Clinical Research Center24
已完成
2 期
Quercetin on thalassemia induced depressioIRCT20091114002709N46Iran University of Medical Sciences84